EBC Statement

A recent European Citizens’ Initiative, ‘Save cruelty free cosmetics – Commit to a Europe without animal testing’, calls for the ‘phasing out of the use of animals in science’ and urges the European Commission to ‘commit to a legislative proposal plotting a roadmap to phase-out all animal testing in the EU before the end of the current legislative term’.

The brain community would like to moderate these demands: a complete ban of the use of animals in biomedical research is premature. Although considerable progress has been made using alternatives, most of what can be learned about the brain and behaviour still depends directly, or indirectly, on research in animal models.

A European brain health strategy and implementation plan is critical to foster innovation to address the high disease burden and to improve the lives of those affected by brain disorders. It is essential to have a joint approach for all brain disorders. The roadmap highlights the need to create an enabling environment which promotes brain health in Europe.

As stressed in many scientific articles and in most of the health authority reports, the impact of COVID-19 on brain health during the last months has been a major and dramatic one, with severe mental and neurological consequences.

This paper presents the results of a European survey led by the French Brain Council to define key priorities for national brain and mental health plans. Based on consensus across multiple countries, it identifies core actions such as improving coordinated and home-based care, reducing regional inequalities in prevention, strengthening evidence-based policymaking, promoting education on innovative technologies, and supporting translational research to better address unmet needs in brain disorders.

Horizon Europe should support robust measures for accelerating brain health research and decreasing the burden of diseases still ailing European citizens, without many effective cures at hand. For example, the global population is ageing and with this comes the steady increased risk and incidence of brain, i.e. neurological and psychiatric, conditions. Addressing health—in particular, brain health—must be a priority for Europe & an example for the rest of the world in addressing the biggest global challenges.

We, as representatives of the undersigned organisations, welcome the current European Commission’s proposal for a new Framework Programme for Research & Innovation, “Horizon Europe”. We acknowledge the budget increase — in spite of the currently challenging financial context — and applaud the many important imp

The human brain is complex. As the control centre of our body, this organ directly affects every function, ranging from rational thinking, emotions, heartbeat, breathing, food and fluid intake, sleep and sexual functions. A healthy brain is the ultimate prerequisite for quality of life and sustainable well-being: yet, in Europe alone, 179 million citizens of all ages with brain disorders, neurological and mental alike, with these numbers increasing steadily. For a continent and Union that strives to build and maintain healthy and prosperous lives for all citizens, disorders of the brain lack the awareness
and recognition they are due. Europeans are growing older and with

The brain is the most complex human organ. It provides and controls virtually every function of the body, ranging from rational thinking, emotions, heart beat, breathing, food and fluid intake, sleep or sex. In a vision of high quality of life and wellbeing, keeping our brain functioning and healthy is a clear prerequisite. Disorders of the brain are extremely complicated to analyse, diagnose and treat in comparison to other diseases. These brain disorders – to name just the
most common ones: depression, Alzheimer’s/dementia, schizophrenia, stroke, migraine, sleep disorders, Parkinson’s disease, pain syndromes (back pain, in particular), addiction to alcohol and other substances- give rise to a far higher level of disability, including admissions to hospitals and nursing homes, than is widely recognised. Health economists have calculated that brain disorders amount to ca. 45% of the annual health budget of Europe, totaling around €800
billion every year.

As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports on each country provide a more specific analysis of MS policy, care and support available for people with MS in each country.

As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports on each country provide a more specific analysis of MS policy, care and support available for people with MS in each country.

As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports on each country provide a more specific analysis of MS policy, care and support available for people with MS in each country.

As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports on each country provide a more specific analysis of MS policy, care and support available for people with MS in each country.

Though recognizing the limits of animal research, animal models often provide unique insights in the functioning of the human nervous system. Fully stopping animal research would therefore harm the efforts of neuroscientists to develop medicines for people living with brain disorders. The EBC thus supports Directive 2010/63/EU that provides a robust and solid framework for animal research.

This document is an overview of suicide in Europe, summarising key data on prevalence, risk and protective factors, and warning signs, as well as outlining evidence-based prevention strategies across healthcare, education, community support, and media guidelines.

This policy white paper outlines key gaps in the understanding, diagnosis, and care of brain disorders in Europe, highlighting insufficient research, limited public and professional awareness, delayed diagnosis, and fragmented health and social care systems. It proposes a shift toward stronger investment in neuroscience research, improved training and awareness, earlier intervention and prevention, and better-integrated care pathways supported by coordinated health services. At system level, it recommends EU-wide collaboration through a comprehensive brain health strategy, shared research infrastructures, and coordinated initiatives to improve knowledge exchange, care quality, and policy implementation across countries.

This consensus statement argues for a major expansion of brain research in Europe, emphasising the urgent medical, humanitarian, scientific, political, and economic need to improve prevention, treatment, and management of brain disorders affecting one in four Europeans. It highlights that significant progress is possible through strong, coordinated collaboration between patients, researchers, clinicians, and industry, and strongly supports the proposed actions to accelerate research and innovation in this field.

The human brain is the most complex living structure known in the universe. This single organ controls every aspect of our bodies, ranging from heart rate to emotion, learning and memory. The brain has enabled humans to achieve breathtaking milestones: walking on the moon, mapping the human genome, or composing masterpieces of literature, art and music. It is the home of our personalities, thoughts, feelings and other human characteristics. It is the ability of the brain to perform all of these functions that makes us human. The brain is a true wonder that needs to be nurtured, protected and cared for.

When the European Brain Council was being formed, one of the primary concerns was how such an organisation would maintain its focus and governing principles. As a coalition of other organisations with their own membership, rules and objectives, there were several issues to be considered. The first of these was to decide which of the many European organisations whose aims are compatible with those of the EBC should become members.

There are many potential benefits from the incorporation of the various EU research and innovation funding initiatives into a single programme. EBC believes that the establishment of the framework would help to ensure that the EU supports high quality research across its Member States, of which Brain disorders plays a major part, but that there should be Green Paper – “From Challenges to Opportunities: Towards a Common Strategic Framework for EU Research and Innovation Funding” greater clarity regarding the prioritisation of the research agenda, which should reflect the needs of society and the citizens from across all of Europe and its’ changing demographics.

This consensus paper updates a previous European Brain Council document on brain research priorities, highlighting the substantial and growing social and economic burden of psychiatric and neurological disorders in Europe, estimated at €386 billion annually and expected to rise with population ageing. It stresses the need for urgent action through strengthened European coordination and investment in basic and clinical neuroscience research. Building on the 2006 consensus, it reflects progress in the field and sets updated priorities based on input from multidisciplinary and multinational experts, aiming to guide policymakers and stakeholders in future research funding and strategy.

A Focus on Persons with Schizophrenia and the European Society

The 3rd European Brain Policy forum, entitled “A Focus on Persons with Schizophrenia and the European Society” was jointly organised by the Spanish Brain Council (SBC) and the European Brain Council (EBC) at the Instituto de Salud Carlos III in Madrid on February 23rd and 24th 2010.

Depression and the European Society

The 2nd European Brain Policy Forum, entitled “Depression and the European Society” took place in Brussels over 25-26 February 2009.

A focus on Parkinson’s Disease and the European Society

The first of a series of annual, multidisciplinary forums launched by the European Brain Council (EBC) to bring stakeholders together to discuss a major brain disease took Parkinson’s disease (PD) as its theme. The goal of the forum was to highlight the imbalance between the societal and individual costs of brain disease, and the resources allocated to dealing with the problem, and to help build a coordinated European research strategy to tackle it better in future. Each forum will open with an analysis of the burden and cost of the disease in question, and will then allow patients, policymakers, scientists, doctors and industry representatives – all those with a stake in disease-related research – to have their say.

The 2008 data from the European Commission showed that 34 million fake medicines were found by European customs authorities in just 8 weeks during 2008. This demonstrates the explosion in counterfeiting when compared to the 2.7 million fake medicines seized during 2006. The European Brain Council believes that counterfeit and substandard medicines represent a serious threat to European Public health and that action is needed to ensure that the legitimate supply chain is secure.

The EBC has followed closely the revision of the Directive 86/609 and, in particular, the European Parliament’s Written Declaration requesting an immediate ban on the use of great apes and wild caught monkeys as well as a timetable for the phasing out of all use of non-human primates. The EBC approves of well-considered efforts to implement the reduction, refinement and replacement (3Rs) of animals in biomedical research in general, and to develop scientifically-based alternatives that have the potential to provide alternative or superior information to that obtained from animals.

This consensus paper highlights the large and growing burden of brain disorders in Europe and argues that research investment is far too low relative to their impact, contributing to scientific and economic decline compared with other regions. It calls for increased, better-coordinated European funding for brain research, stronger collaboration across sectors, and a strategic research agenda to improve understanding, treatment, and prevention of brain diseases.

In neuroscience, the term ‘Stress’ has a negative connotation because of its potential to trigger or exacerbate psychopathologies. Yet in the face of exposure to stress, the more common reaction to stress is resilience, indicating that resilience is the rule and stress-related pathology the exception. This is critical because neural mechanisms associated with stress-related psychopathology are expected to differ significantly from those associated with resilience.

Novel analyses of the nervous 13 systems of vertebrates allow retracing the occurring evolutionary changes with unprecedented 14 precision using new technical tools from molecular biology, immunocytochemistry or molecular 15 genetics. These analyses reveal the evolution of particular brain structures in new environments and 16 their relation to different life styles, something that biologists call an “ecological niche”.

The French Brain Council, which has a balanced representation of Neurology, Psychiatry and Neurosciences, participated in the launch of a survey on the current status of care for patients suffering from brain diseases with the aim to identify 10 consensual priorities to be emphasized in the building the National Brain Plan in all European member states. This National Brain and Mental Health plan was approved by the National Brain Councils of 17 European member states. The present report details the 11 responses that obtained a consensus, the top five (over 90% of agreement) being the needs to: (1) improve multidisciplinary integrated home care and structures of coordinated health care, (2) increase homogeneity within regions for current state of prevention, (3) develop evidence based and socially responsible policy by collecting data from ongoing clinical trials and basic research to optimally address unmet needs, (4) promote education on innovative technologies, and (5) facilitate translational research.